NCT03669991Unknown不适用
Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary
Chinese Academy of Medical Sciences, Fuwai Hospital1 个研究点 分布在 1 个国家目标入组 2,200 人开始时间: 2018年8月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 2,200
- 试验地点
- 1
- 主要终点
- Major adverse cardiovascular and cerebrovascular events (MACCE)
研究概览
简要总结
The study is aimed to optimized the dose-adjusted regimen of beta-blockers in patients with acute coronary syndrome by investigating therapeutic and curative results of target doses Beta-blockers using the dose-adjusted pathway of beta-blockers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Patients diagnosed as acute coronary syndromes including acute ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevated acute coronary syndrome (NSTE-ACS)
- •Patients or whose legal representatives signed written informed consent form
排除标准
- •Patients should been excluded if they meet any of the following exclusion criteria:
- •Patients with contraindications to the application of beta blockers, including: 1) cardiogenic shock or heart failure (Killip grade > II level);2) sick sinus syndrome; 3) II degree atrioventricular block;4) unstable decompensation of cardiac failure (pulmonary edema, hypotension or low perfusion); 5) symptomatic hypotension or bradycardia (heart rate<50 beats/min, blood pressure<90/60mmHg); 6) contraindications to beta blockers or allergy to any ingredient of beta blocker; 7) active asthma should be treated by inhalation preparation treatment
- •Pregnant or lactating women
- •Patients without signed written informed consent
- •Patients who was considered by the researcher inappropriate to participate in this study (for example, patients with a higher risk of cardiogenic shock, etc.)
结局指标
主要结局
Major adverse cardiovascular and cerebrovascular events (MACCE)
时间窗: Within 1 year after surgery
MACCE were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), stent thrombosis (ST) and stroke.
次要结局
- Serum norepinephrine(Within 1 year after surgery)
- Resting heart rate(Within 1 year after surgery)
- Ejection fraction(Within 1 year after surgery)
- Blood pressure (systolic & diastolic)(Within 1 year after surgery)
研究者
Yi-Da Tang
Professor
Chinese Academy of Medical Sciences, Fuwai Hospital
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Impact of Beta Blockers on TAVI (BETA-TAVI)Aortic Valve StenosisNCT05721170National and Kapodistrian University of Athens347
已完成
4 期
Beta Blocker Therapy in Moderate to Severe COPDChronic Obstructive Pulmonary DiseaseNCT01656005University of Dundee18
已完成
不适用
Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central ChinaAcute Coronary SyndromeNCT03116854Henan Institute of Cardiovascular Epidemiology3,000
已完成
不适用
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)Pulmonary Disease, Chronic ObstructiveNCT02719639Boehringer Ingelheim7,443
招募中
不适用
Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)Aortic StenosisNCT06472934University Hospital, Basel, Switzerland498